2022-RA-221-ESGO HYSTERECTOMY ALONE VS. HYSTERECTOMY PLUS SENTINEL NODE MAPPING IN ENDOMETRIAL CANCER: LONG-TERM RESULTS FROM A MULTI-**INSTITUTIONAL STUDY**

¹Giorgio Bogani, ²Violante Di Donato, ³Andrea Papadia, ⁴Alessandro Buda, ⁵Jvan Casarin, ⁵Fabio Ghezzi, ⁶Roberto Angioli, ⁷Francesco Plotti, ⁷Daniela Luvero, ⁸Fabio Landoni, ⁹Pierluigi Benedetti Panici, ¹⁰PierAndrea de Iaco, ¹⁰Myriam Perrone, ¹¹Flavia Sorbi, ¹²Simone Ferrero, ¹³Michel Mueller, ¹⁴Francesco Raspagliesi. ¹Gynecologic Oncology, La Sapienza of Rome, Rome, Italy; ²University La Sapienza of Rome, Roma, RM, Italy; ³University of Lugano, Lugano, Switzerland; ⁴Michele e Pietro Ferrero Hospital. Verduno. Italy; ⁵University of Insubria, Varese, Italy; ⁶Campus Biomedico, Rome, Italy; ⁷Campus Biomedico, Roma, RM, Italy; ⁸University Milano Bicocca, Monza, Italy; ⁹University La Sapienza of Rome, Rome, Italy; 10 University of Bologna, Bologna, Italy; 11 University of Firenze, Florence, Italy; 12 University of Genova, Genova, Italy; 13 University of Bern, Bern, Switzerland; ¹⁴Fondazione IRCCS Istituto Nazionalw dei Tumori di Milano, Milano, Italy

10.1136/ijqc-2022-ESGO.207

Introduction/Background To compare outcomes after hysterectomy and hysterectomy plus sentinel node mapping (SNM) in endometrial cancer (EC) patients.

Methodology This is a retrospective study, collecting data from EC patients treated between 2006 and 2016 in nine referral centers.

Results The study population included 398 (69.5%) and 174 (30.5%) patients having hysterectomy and hysterectomy plus SNM. As the results of the adoption of a propensity-score matched analysis, we selected two homogeneous cohorts of patients (150 having hysterectomy only vs. 150 having hysterectomy plus SNM). The execution of sentinel node mapping correlated with longer operative time, but it is not influencing the length of hospital stay and estimated blood loss. Overall severe complication rates were similar between groups (0.7% in the hysterectomy group vs. 1.3% in the hysterectomy plus SNM group; p=1.00). No lymphatic-specific complication occurred. Overall, 12.6% of patients having SNM were diagnosed with disease harboring in their lymph nodes. Adjuvant therapy administration rate was similar between groups. Considering patients having SNM, 4% of patients received adjuvant therapy on the basis of nodal status only; all the other patients received adjuvant therapy on the basis of uterine risk factors. Five-year disease-free (p=0.720) and overall (p=0.632) survival was not influenced by the surgical approach.

Conclusion Hysterectomy (with or without SNM) is a safe and effective method for managing EC patients. Potentially, these data support the omission of side-specific lymphadenectomy in case of unsuccessful mapping. Further evidence is warranted to confirm the role of SNM in the era of molecular/genomic profiling.

2022-RA-257-ESGO

THE VALUE OF DIFFERENT FRAILTY INDICES IN PREDICTING SHORT-TERM **POST-OPERATIVE OUTCOMES**

^{1,2}Monika Sobocan, ²Kaja Gril Rogina, ²Eva Pavla Malovrh, ^{1,2}Jure Knez. ¹Division for Gynaecology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia; ²Faculty of Medicine, University of Maribor, Maribor, Slovenia

10.1136/ijqc-2022-ESGO.208

Introduction/Background Endometrial cancer is the most common gynaecological malignancy and is treated primarily surgically. An increasing body of evidence suggests frailty is an important predictor of postoperative morbidity. Yet, data on pre-operative assessment tool use to assist surgical decision making is limited. This study sought to assess different surgical decision making tools for assessing the impact of frailty on short-term postoperative outcomes.

Methodology A patient record review was performed for patients diagnosed and primarily surgically treated between January 2015 and December 2016 for endometrial cancer at the University Medical Centre Maribor, Slovenia. Records of patients were evaluated through the use of different frailty indexes; the modified Frailty Index-5 (mFI-5), 11-factor modified frailty index (mFI-11), frailty deficit index (FDI) and Memorial Sloan Kettering Frailty Index (MSK-FI). Scores were recorded and correlated with short-term patient outcomes as well as patient characteristics. Primary outcomes were 45-day Clavien-Dindo rated complications, length of postoperative stay (LOS) and 45-day emergency services visits (ER).

Results Seventy-three women, median age 65 years (min 41 years - max 87 years) were included. Median LOS was 4 (min 1 - max 21) days. 24 women (33%) had post-operative complications resulting in a deviation from standard early postoperative care. Amongst those, experiencing complications within 45 days after surgery, 7 (10%) had stage I complications, 16 (22%) stage II complications and 2 (3%) stage III complications. Older women (above 60 years) had significanlty higher BMI (p<.001), but age was not a significant determinant of LOS. All evaluated frailty scales showed significant increases in women above 60 as well as 70 years of age. No specific cut-off was found to be significant for predicting short-term post-operative complications.

Conclusion Different additional tools should be further evaluated to determine most appropriate assessment methods to assist surgical decision-making in identifying and preparing frail patients for treatment.

2022-RA-295-ESGO

CIRCULATING CELL FREE DNA AND CITRULLINATED HISTONE H3 AS USEFUL **BIOMARKERS OF NETOSIS IN ENDOMETRIAL CANCER**

¹Livia Ronchetti, ²Irene Terrenato, ²Margherita Ferretti, ³Giacomo Corrado, ²Frauke Goeman, ²Sara Donzelli, ²Chiara Mandoj, ²Roberta Merola, ²Ashanti Zampa, ²Mariantonia Carosi, ²Giovanni Blandino, ²Laura Conti, ²Anna Maria Lobascio, ²Marcello Iacobelli, ²Enrico Vizza, ²Giulia Piaggio, ⁴Aymone Gurtner. ¹Regina Elena Cancer Institute, Rome, Italy; ²Regina Elena National Cancer Institute, Rome, Italy; ³Department of Women and Children Health, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy; ⁴National Research Council (CNR), Rome, Italy

10.1136/ijqc-2022-ESGO.209

Introduction/Background Cancer mortality is mainly caused by organ failure and thrombotic events. NETosis, a chromatin release mechanism implemented by neutrophils, may contribute to these systemic effects. Our aim was to determine the occurrence of NETosis in endometrial cancer (EC) and analyzing tissue and serum NETosis biomarkers in EC patient to identify possible new targets for EC stratification and treatment.

Methodology Experiments were conducted on 63 EC patients (ranging from G1 to G3 grade) and 21 healthy controls (HC). Immunohistochemistry (IHC) and Immunofluorescence (IF) was performed on tumor tissue sections using antibodies against citrullinated histone H3 (citH3) (a marker of NETosis), neutrophil elastase (NE) and H2B. Serum levels of circulating free DNA (cfDNA), circulating free mitochondrial DNA (cfmtDNA) and citH3 were measured by qPCR using one microliter of deactivated serum, and by ELISA assay respectively. Fragmentation pattern of serum cfDNA was analyzed using the Agilent 2100 Bioanalyzer and High Sensitivity DNA Chips. Receiver operating characteristic (ROC) analysis was used to identify a cut off for cfDNA and cfmtDNA values able to discriminate EC from HC. Multiple correspondence analysis (MCA), between cfDNA, mtcfDNA, citH3 and blood parameters were used to identify associations among serum parameters in EC.

Results NETosis is activated in all EC grades. In EC sera, elevated cfDNA concentration is associated with citH3 in G1 and G2 EC. Categorizing by ROC cut off cfDNA and cfmtDNA value distributions, we observed that citH3 levels are significantly higher in samples with high values of cfDNA and low values of cfmtDNA A specific cfDNA fragmentation pattern characterizes EC and correlates with citH3 serum levels.

Conclusion NETosis could represent a new therapeutic target concerning EC. The combination of three serum parameters, citH3, cfDNA and cfmtDNA could be useful to monitor NETosis by non-invasive liquid biopsies opening the way for new therapeutic strategies in EC.

2022-RA-376-ESGO

CLINICOPATHOLOGICAL CHARACTERISTICS OF 'MULTIPLE-CLASSIFIERS' IN ENDOMETRIAL CANCER

¹Luigi Antonio de Vitis, ^{1,2}Gabriella Schivardi, ¹Giulio Bonaldo, ^{3,4}Caterina Fumagalli, ⁵Paola Rafaniello Raviele, ¹Maria Teresa Achilarre, ¹Alessia Aloisi, ¹Annalisa Garbi, ¹Mariateresa Lapresa, ¹Gabriella Parma, ¹Vanna Zanagnolo, ^{1,6}Giovanni Damiano Aletti, ^{5,6}Elena Guerini-Rocco, ²Andrea Mariani, ¹Angelo Maggioni, ⁵Massimo Barberis, ^{1,7}Nicoletta Colombo, ¹Francesco Multinu, ¹Ilaria Betella. ¹Department of Gynecology, European Institute of Oncology, Milan, Italy; ²Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN; ³Clinical Unit of Oncogenomics, European Institute of Oncology, Milan, Italy; ⁴Department of Diagnostic Services, Division of Pathology, ASST Valle Olona, Gallarate, Italy; ⁵Department of Pathology, European Institute of Oncology, Milan, Italy; ⁶Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; ⁷Faculty of Medicine and Surgery, University of Milan Bicocca, Milan, Italy

10.1136/ijqc-2022-ESGO.210

Introduction/Background According to the molecular classification, most endometrial cancers(ECs) can be categorised based on a unique molecular signature (e.g., POLE-mutation, mismatch-repair(MMR)-deficiency, p53-abnormality). However, a small number of cases harbour more than one molecular feature and are referred as 'multiple-classifiers'. The aim of the study is to describe the clinicopathological and molecular characteristics of multiple-classifier ECs.

Methodology Among all ECs undergoing a comprehensive molecular analysis at European Institute of Oncology, Milan, between April 2019 and December 2021, 'multiple-classifiers' were identified. Clinicopathological and molecular characteristics were collected from electronic medical records. The molecular analysis consisted of immunohistochemistry for p53 and MMR proteins, microsatellite instability assay, and Next Generation Sequencing (NGS) for POLE exonuclease domain and TP53. ECs were considered p53-abnormal if either immunohistochemistry or NGS resulted altered, MMR-deficient if either proteins expression was abnormal or mismatch-repair instable and POLE when pathogenic POLE mutations were found. ECs were

molecularly classified according with WHO-endorsed algorithm. To compare continuous and categorical variables Wilcoxon-Mann-Whitney test and chi-square test were used, respectively. Proportions are reported as number (percentage and 95% confidence interval(CI)).

					Tabl	e 1a. Multiple-classifier o	laissa athalasis	d sharpeteriotics			
Molecular group	ID	Age (years)	8MI	LND Metastasis		Histotype	Grade	LVSI	Risk class* (molecular	Risk class* (molecular	Adjuvant Treats
		rige (years)	(kg/m2) 21.9	UND MICLISCASIS	IA IA	Endometroid	Grade 1	No	unknown) Law	known) (ow	No.
POLEmut-MMRd	2	47	19.6	пс	IA.	Endometroid	Grade 2	No	Low	Low	No
	3	42	25.5		IA.	Endometroid	Grade 1	No Diffuse	Low	Low	No CHT + EBRT +
POLEmut-p53abn	- 4	51 75	28.3		IB IA	Clear cell Endometroid	Grade 3 Grade 3	No	High Intermediate	High Low	CHT + EBRT +
	6	44	19.3		IA	Endometroid	Grade 3	No	Intermediate	Low	No
	7	54	24.2		IA	Endometroid	Grade 1	No	Low	Low	No
	- 8	57 76	19.5	Macro	IA IIC1	Endometroid Undifferentiated	Grade 2 Undifferentiates	No d Diffuse	Low	Low	No CHT*
	10	55	20.1	Macro	IIC1	Endometroid	Grade 3	d Diffuse No	High High-intermediate	High High-intermediate	EBRT + VB
	11	59	31.1		IA.	Endometroid	Grade 1	No	Low	Low	No
	12	55	33.6		IA.	Endometroid	Grade 1	No	Low	Low	No
	13	69 84	17.5		IA IA	Clear cell Serous	Grade 3 Grade 3	Focal	Intermediate Intermediate	Intermediate	No No
	15	74	20.5		IA IA	Serous Endometroid	Grade 3 Grade 2	No No	Intermediate	Intermediate	No.
MMRd-p53abn	16	63	23.3	Macro	IVB	Endometroid	Grade 3	Focal	Advanced/Metastatic	Advanced/Metastatic	CHT
	17	54	26.7	Macro	IIC1	Endometroid	Grade 3	No	High	High	CHT + EBRT +
	18	78	28.7		IA	Endometroid	Grade 3	No	Intermediate	Intermediate	No
	19	69	33.2	пс	IA IIIA	Endometroid Endometroid	Grade 2 Grade 2	No No	Low	Low	No OHT
	21	50	32.8	Macro	IIC1	Endometroid	Grade 2	No	High	High	CHT + EBR
	22	60	27.7	Macro	IIC2	Endometroid	Grade 3	Diffuse	High	High	CHT + EBR
	23	67 58	25.3		IV8	Mixed Mixed	Grade 3	No No	Advanced/Metastatic	Advanced/Metastatic	CHT + EBRT +
POLEmut-MMRd-	- 24										
p53abn Abbreviations BMI, body available; POLLmut, POL	25	59	24.9 nr FBRT exten	nal beam radiotherap il brachytherapy; "Ao	LA c. FIGO, The Inter ording to ESGO/I	Endometroid	Grade 3 ogy and Obstetrics; If	No FC, isolated turnor cells;	High Intermediate UNO, Lamph node; EVSI, Tymph-vasoul	High Low ar space invasion; MMH-d, mismet	No.
Abbreviations BMI, body available: POLEmut, POL Molecular group	25 mess index; c mutated; pt	59 Diff, chemothers Jabh, p53 abnor	24.9 py: EBRT, extenset VB, vegino	i brachytherapy; *Ao	MA g. FIGO, The Inter profing to ESGO/I MMR pro	Endometroid mational Fedoration of Gyneco ISTRG/ISP 2020, * Relapsed.	Grade 3 ogy and Obstetrics; If ier molecular cha stry MSI	No FC, isolated turnor cells;	Intermediate	Low ar spece invasion; MMR-d, mismet	No ch repair-deficient, ne
Abbreviations: BMI, body available; POLEmut, POL	25 mess index; git invasted; g	59 Diff, themothers Jabbs, p53 abnor POLI exon 9 p.Ser2 exon 9 p.Pro	24.9 py; EHT, external, VB, vaginal i mutation 97Phe (p.SZ 26Arg (p.PZ	(NGS) (NGS) (NGS) (NGS) (NGS) (NGS)	M c FGO, The Inter- ording to ESGO/I MMR pro MLH 1 +, PI MLH 1 -, PI	Endometroid metocal ledoraton of Gyneco ISTRO/ISP 2003. * Relapsed. Table 1b. Multiple-classif rtein immunobistochemi MS2 +, MSH6 -, MSH2 + MS2 -, MSH6 +, MSH2 +	Grade 3 ogrand Obstetrice; if ier molecular cha ttry MSI MSI-high MSS	No PC, toolsted tumor celt; aracteristics. WT WT	Intermediate UNO, Lamph node; LYO, lymph-rascol TPS3 mutation (NGS)	Low or space invasion, MMM-d, mismet P53 imms	No ch repair-deficient, ne
Abbreviations BMI, body available: POLEmut, POL Molecular group	ID 1 POLE 2 POLE 3 POLE	59 Diff, chemothers Jabb, p53 abnor POU exon 9 p.Ser2 exon 9 p.Proi exon 14 p.Ala	24.9 py; CBT, extended to the control of the contro	(NGS) (NGS) (1977) c.890C-T (1864) c.857C-G (456P) c.1366G-C	MMR pro MLH 1 +, PI MLH 1 -, PI MLH 1 +, PI	Endometroid matoral l'edoraton of Gyneco ISTRO/ISP 2003. Relipsed. Table 1b. Multiple-classif stein immunohistochemi MS2+, MSH6-, MSH2+ MS2-, MSH6-, MSH2+ MS2+, MSH6-, MSH2+	Grade 3 ogy and Countries, if ier molecular cha itry MSI MSI-high MSS MSS	No IC, noisted tumor celu, aracteristics. WT WT TP53 exon 8 p.Argi	Intermediate UKO, Lymph node, LVD, Ayroph-socol TP53 mutation (NGS) 306Ter (p.R213*) c.916C>T	Low ar space invasion, MMM-4, mismed P53 imme NA NA aberrant	No ch repair-deficient, ne
Abbreviations BMI, body available: POLEmut, POL Molecular group	ID 1 POLE 2 POLE 3 POLE 4 POLE POLE POLE	POUL exon 9 p.Ser2 exon 9 p.Ser2 exon 14 p.Ala exon 13 p.Va exon 9 p.Ser2	24.9 py, 1941, external V0, vagno mutation 97Phe (p.S2 96Acg (p.P2 456Pro (p.A 411Leu (p.V 97Phe (p.S3)	(NGS) (NGS) (NGS) (NGS) (NGS) (NGS)	MAR PROOF THE PR	Endownetoeld resolved Federation of Greeco 153980/159 2003. * Relapsed. Table 1b. Multiple-classiff teteln immunohistochemi MS2+, MS96 -, MS912 + MS2+, MS96 -, MS912 +	Grade 3 ogs and Observice; It ier molecular cha futry MSI MSI-high MSS MSS MSS MSS MSS MSS	No TC, noisted tumor cells, aracteristics. WT WT TP53 exon 8 p.Arg1 TP53 exon 6 p.Arg2 TP53 exon 7 p.Cys2	Intermediate UIG. Limph rode. USA, Imph-vascul TPS3 mutation (NGS) 1006Ter (p.R213*) c.916C-71 213Ter (p.R213*) c.637C-7 213Ter (p.R213*) c.637C-7 213EGy (p.C238G) c.712T>G	Low ar space invasion; MMH-4, mismet P53 Imms NA NA	No ch repair-deficient, ne
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	ID 1 POLE 2 POLE 4 POLE 5 POLE 6 POLE 6 POLE	POUL exon 9 p Ser exon 9 p Pro exon 14 p Ala exon 13 p Va exon 14 p Ala exon 19 p Ser exon 14 p Ala exon 19 p Ser exon 14 p Ala exon 19 p Ser exon 14 p Ty	24.9 pr. EHT, extensit VII, vapos i mutation (979he (p.53 856ho (p.84 456ho (p.84 979he (p.53 458ho (p.87 886ho (p.87 886ho (p.87 886ho (p.87 886ho (p.87	(NGS) 1977) c.8900-T 1864) c.8570-G 4569) c.18660-C 4111) c.1231-Go 4411) c.1231-Go 4589) c.18570-G	MAR PRODUCTION TO STAND THE PRODUCTION THE	Endometroid Findometroid Fin	Grade 3 ogs and Observice; It ier molecular cha thry MSI MSI-high MSS MSS MSS MSS NA	No TC, notated tumor celts. WT WT TPS3 exon 8 p.Arg; TPS3 exon 9 p.Arg; TPS3 exon 7 p.Cyn;	Intermediate UIO, Lymph rode, LYS, Lymph-vascul TP53 mutation (INGS) 1007er (p.R213*) c.916C>7 1213Fer (p.R213*) c.637C>7 1213Fer (p.R213*) c.637C>7 1275Cys (p.R2135*) c.537C>7	Low ar speci invision, MMH, d. inbrinds P53 limms NA NA aberrant W// equivocal W//	No ch repair-deficient, ne
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	ID 1 POLE 2 POLE 4 POLE 5 POLE 6 POLE 7 POLE 7 POLE	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, vogen and the property of the propert	(NGS)	MA (FROOL The Interest and Inte	Endownetoeld resolved Federation of Greeco 153980/159 2003. * Relapsed. Table 1b. Multiple-classiff teteln immunohistochemi MS2+, MS96 -, MS912 + MS2+, MS96 -, MS912 +	Grade 3 ogs and Obstervice; if ier molecular cha try MSI MSI-high MSS MSS MSS MSS MSS NAS MSS NAS	No TC, solated tumor celt. WT WT TPS3 exon 8 p.Arg; TPS3 exon 7 p.Cyg TPS3 exon 5 p.Arg; TPS3 exon 5 p.Arg;	Intermediate UGL Lemph rode, IDSL yepph-resoul TP53 mutation (NGS) 3005Ter (p.R213*) c.916C-7 213Ter (p.R213*) c.637C-7 228GV (p.C236G) c.7227-6 275CV (p.R275C) c.523C-7	Low ar special invasion, MMM-I, inhuned PS3 Immo NA NA NA aberrant WI equivocal WT equivocal	No ch repair-deficient, ne
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	ID 1 POLE 2 POLE 3 POLE 5 POLE 5 POLE 6 POLE 7 POLE 8 POLE 8 POLE 8 POLE 8 POLE 9 POL	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, vogen and the property of the propert	(NGS) 1977) c.8900-T 1864) c.8570-G 4569) c.18660-C 4111) c.1231-Go 4411) c.1231-Go 4589) c.18570-G	MMR production of MHH1+, PI MMH1+, PI	Endometroid Findometroid Fin	Grade 3 ogs and Obstervice; if ier molecular cha try MSI MSI-high MSS MSS MSS MSS MSS NAS MSS NAS	No TC, solated tumor celt. WT WT TPS3 exon 8 p.Arg; TPS3 exon 7 p.Cyg TPS3 exon 5 p.Arg; TPS3 exon 5 p.Arg;	Intermediate UIO, Lymph rode, LYS, Lymph-vascul TP53 mutation (INGS) 1007er (p.R213*) c.916C>7 1213Fer (p.R213*) c.637C>7 1213Fer (p.R213*) c.637C>7 1275Cys (p.R2135*) c.537C>7	Low or speed invasion, MMM-d, mismed P53 Imme NA NA abbrevant W/f equivocal W/f equivocal Not (valuable)	No No repart deficient, na unohistochemiste
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	ID 1 POLE 2 POLE 5 POLE 5 POLE 6 POLE 7 POLE 8 POLE 9 WT 10 WT	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, vogen and the property of the propert	(NGS)	MMR pro MHH1-, P	Endomentoid Francisco al flow in or of On-economics of Color on One One One One One One One One One On	Grade 3 opy and Oceanines; if iter molecular chair iter molecular chair iter MSI MSS-high MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No TC holated turnor cell. aracteristics. WT WT TPS3 exon 8 p.Arg TPS3 exon 6 p.Arg	Intermediate USL tumph rode, IDSL prepriseous TP53 mutation [NG5] TP53 mutation [NG5] 100Ter (p.R213*) c.916C-T 213Ter (p.R213*) c.637C-T 213Ter (p.R213*) c.637C-T 213Ter (p.R213*C c.537C-T 213Ter (p.R213*C c.537C-T 213Ter (p.R213*C c.637C-T 213Ter (p.R213*C c.637C-T 213Ter (p.R213*C c.637C-T 213Ter (p.R213*C) c.637C-T	Low P53 Immo NA NA NA WT equivocal WT equivocal Not (valuable Agerrant on WT MY MY MY MY MY MY MY MY MY M	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	1D 1 POLE 2 POLE 5 POLE 5 POLE 6 POLE 7 POLE 8 POLE 9 WT 10 WT 11 WT 11 WT 11 WT 11 WT 11 WT 11 WT	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, vogen and the property of the propert	(NGS)	MMR pro MUH1+, PI MUH1-, PI	Endomentoid Front of Control of Grants Front of Control of Grants Front of Control Front of Contro	Grade 3 opy and Oceanines. If iter molecular chail iter molecular chail itery MSI MSI-high MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No TC, to listed turnor cell, ar acteristics. WT WT TPS1 exon 8 p.Arg; TPS3 exon 6 p.Arg; TPS3 exon 6 p.Arg; TPS3 exon 8 p.Arg;	Intermediate USL Lemph rode, LOSL, yepph-rode, USL Lemph rode, LOSL, yepph-rode, TP53 mutation (NGS) 1793 mutation (NGS) 1006 for (p. R211*) C 916C-7 1218 of (p. R211*) C 916C-7 1275 of (p. R211*) C 917C-7 1275 of (p. R211*) C 937C-7 1221 of (p. R212*)	Low F3 Inner NA NA NA Abernan VIT equivocal Not Evaluable abernan VIT conductor VIT conductor Not Evaluable Abernan VIT conductor Not Evaluable Abernan VIT conductor Not Evaluable Abernan VIT conductor VIT conductor VIT conductor VIT conductor VIT conductor Condu	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	25 mass index, grant policy (a mutated; grant policy) (b) 1 POLE 2 POLE 3 POLE 5 POLE 6 POLE 7 POLE 8 POLE 9 WT 11 WT 12 WT 11 WT 12 WT	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro MMH = P	Endomentals Transition of Conference of Con	Grade 3 Grade	No TC holded turnor cell. WT TP53 exon 8 p.Arg; TP53 exon 9 p.Arg; TP53 exon 5 p.Arg; TP53 exon 5 p.Arg; TP53 exon 5 p.Arg; TP53 exon 6 p.Arg;	Intermediate UC (amph node, 1075, prephrenou) 1753 mutation (NGS) 1753 mutation (NGS) 1007er (p.8219*); c.9107-1 1217er (p.8219*); c.9107-1 1217er (p.8219*); c.9207-1 1227er (p.8219*); c.9307-1 1227er (p.8219*); c.6307-7 1227er (p.8219*); c.6307-7 1227er (p.8219*); c.9404-7 1227er (p.8219*); c.95007-1 1227er (p.8219*); c.9	Low PS3 Inmo NA NA NA NA NA aberant VIT equinceal VIT control	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	ID 1 POLE 2 POLE 3 POLE 5 POLE 5 POLE 6 POLE 7 POLE 8 POLE 9 WT 10 WT 11 WT 12 WT	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro MH1+, PI MH1+, PI MH1-, PI	Endomentoid Francisco d'Gorces (Grancisco Gorces) Table 1b. Multiple-classifi MS2 - MS86 - MS92 - MS98 - MS98 - MS92 - MS98 - MS98 - MS92 - MS98 - MS92 - MS98 - MS92 - MS98 - MS92 - MS98 - MS98 - MS92 - MS98 -	Grade 3 Grade	No To bished coron cells, wr TPS1 exon 8 p.Arg; TPS3 exon 8 p.Arg;	bitemediate VIC (amph node 1070; prephressor TP33 mutation (NGS) 1000Ter (p.8213*); e360-T 21316* (p.8213*); e370-T 2275**********************************	Cole P33 Imms P33 Imms NA NA Berrent WT equincal NC (cole; 67/66 (67/66 (67/66)) Exercised VC (cole; 67/66 (67/66)) Berrant Decrease Berrant Berrant Berrant Berrant Berrant	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	1D 1 POLE 2 POLE 3 POLE 5 POLE 10 WT 11 WT 12 WT 11 WT 12 WT 11 WT 12 WT 11	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MAN 1- P MUH 1- P	Endomentals Traction of Control of Control Traction of Control Tracti	Grade 3 op and Centerico, if iner molecular chai fory MSI MSI-high MSS-high MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No TC, ordered amor cells, TC,	Intermediate (IXC Lorgh robots)	Use P53 Imme P53 Imme NA NA NA NA NA Servant WT equivocal her Coolsele work of Coolsele her Coolsele work WT Coolsele her Coolsele work WT WT berrant berrant berrant berrant berrant berrant	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	1 POLE 5 POLE 6 POLE 7 POLE 9 WT 12 WT 13 WT 15 WT 15 WT	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MAN 1- P MAN 1- P	Endomentals Trained and Conference of Concession of Conce	Grade 3 for and Common. If for molecular chair for molecular chair for molecular chair for molecular chair for MSI-high MSI-high MSS MSS MSS NA MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No. "Covined inno cell," "Covined inno cell, "Covined inno cell, "W? "W? "W? "P53 seen 8 p Arg; "P53 seen 6 p Arg; "P53 seen 8 p Arg; "P53 seen 9 p Arg; "P54 seen 9 p Arg; "P55 seen 9 p Arg; "P	bitemediate VIC (amph node 1070; prephressor TP33 mutation (NGS) 1000Ter (p.8213*); e360-T 21316* (p.8213*); e370-T 2275**********************************	Use P53 Imme P53 Imme NA NA NA NA NA Servant WT equivocal her Coolsele work of Coolsele her Coolsele work WT Coolsele her Coolsele work WT WT berrant berrant berrant berrant berrant berrant	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbreviation: BM, bob available: POLEmus, POL Molecular group POLEmut-MMRd	25 mass red, git and red, git a	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro- MMH1-, PI	Endomentals **Control of Gyraco **Control **C	Grade 3 Operand Centerros, if iner molecular cha fary MSI MSS-high MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No No C, coled furnior of b, WT WT WT WT WT WT WT WT WT W	Discommission (NG Loral) node (DS) preference (NG Loral) node (DS) preference (NG Loral) node (DS) preference (NG Loral) node (DS) (NG LORAL) node (DS) (NG LORAL) node (DS) (NG LORAL) node (DS) (NG LORAL) node (NG LORAL) n	Use P53 Imme P53 Imme NA NA NA NA NA Servant WT equivocal her Coolsele work of Coolsele her Coolsele work WT Coolsele her Coolsele work WT WT berrant berrant berrant berrant berrant berrant	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 mass reduce, gill and a second process of the second process of	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro MUH1+, PI MUH1-, P	Endownesteid Front of Coversor	Grade 3 ogs and Description, ill ear molecular cha fory MSI MSI-high MSS-high MSS MSS MSS MSS MSS MSS MSS MSS MSS MS	No. C, orderd turnor only, arracteristics. WT WT WT WT WF53 enco 6 μ.Αχ2 WF54 en	Disconnellate (NCC) preference (NCC) pre	Low P3 Inner P53 Inner P53 Inner P53 Inner MM	No th repart deficient, na unablistochemiate unablistochemiate en expression patri
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 mutatroc; gill policy and poli	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR products to SOON MRR produ	Endomentals Trained and Control of Concrete Trained and Concrete	Grade 3 Operand Centerino, III International	No To observation of the control of	Discommission (NG Loral) node (DS) preference (NG Loral) node (DS) preference (NG Loral) node (DS) preference (NG Loral) node (DS) (NG LORAL) node (DS) (NG LORAL) node (DS) (NG LORAL) node (DS) (NG LORAL) node (NG LORAL) n	Cow To specification (Cow) F33 Immu NA NA Abersant VII egginocal Not Crubashi Sherrant Colf. (GPAPA Not Crubashi Sherrant Sherrant Sherrant Sherrant Not Crubashi Sherrant Not Crubashi Sherrant Sherrant Sherrant Sherrant Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant	No. No repair different, re unanohistoche mista unanohistoche mista unanohistoche unan
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 mass reduce, gill and a second process of the second process of	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro- MMH1-, PI	Endownesteid Front of Coversor	Grade 3 Operand Oberstrick (In America) For molecular chair For MSI MSS MSS MSS MSS MSS MSS MSS MSS MSS	No Condend tumor only, arectoristics. W7 W7 W8 W7 W8 W7 W8 W8 W8 W8	Disconnellate (NCC) preference (NCC) pre	Cow To specification (Cow) F33 Immu NA NA Abersant VII egginocal Not Crubashi Sherrant Colf. (GPAPA Not Crubashi Sherrant Sherrant Sherrant Sherrant Not Crubashi Sherrant Not Crubashi Sherrant Sherrant Sherrant Sherrant Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant NA Sherrant	No. No repair different, re unanohistoche mista unanohistoche mista unanohistoche unan
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 Enutation pictures and pictures and pictures and pictures pictures pictures and	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MAN IN MINISTRAL PROPERTY OF THE PROPERTY OF T	Indianental and a second and a	Grade 3 gg and Oberstrock (6 for molecular chair fory MSI MSS MSS MSS MSS MSS MSS MSS MSS MSS	No Condend Tumor only, an accordinate, an accordinate, W7 W7 W7 W8 W8 W7 W8 W8 W8 W8	Disconnellate (ID Iran) rook (100 year) rook (ID Iran) rook (100 year) rook (ID Iran) rook (100 year) rook (ID Iran) rook (ID Iran) (ID Iran) rook (ID Iran)	Tow PS3 Inner PS3 Inner NA NA NA NA PS3 Inner NA NA NA NA NA NA NA NA NA N	No. No repair different, re unanohistoche mista unanohistoche mista unanohistoche unan
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 Pout 1	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.52 86Arg (p.P2 456Pro (p.J. 4	(NGS)	MMR pro (MMR) pr	Todomorbid Todomo	Grade 3 Grade	No Control to the co	bitemediate (OL) (1994 present	Low PS3 Inmo NA	No. No repair different, re unanohistoche mista unanohistoche mista unanohistoche unan
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 Enutation pictures and pictures and pictures and pictures pictures pictures and	POUR chemothers also, p53 abnormal p Series on 9 p Series on 14 p Alle exon 14 p Alle exon 14 p Alle exon 14 p Person 14 p Person 14 p Person 14 p Person 19 p Per	24.9 pr. EBRT, extended, voges of mutation 97Phe (p.53 86Arg (p.P2 456Pro (p.J 456Pro (p	(NGS)	MAN IN MINISTRAL PROPERTY OF THE PROPERTY OF T	Indianental and a second and a	Grade 3 ge and Consentraci (ii) filer molecular cha fory MSA MSA MSS MSS MSS MSS MSS MSS MSS MSS	No No Control favor only, aracteristics, work WT TP51 enco fig. p.	Distribution Dist	Low P3 Immer P3 Immer P3 Immer P3 Immer P4 Immer P5 Immer	No.
Abbrevistons BMI, borbaralistic POLEmut, POL Molecular group POLEmut—MMRId POLEmut—953abn	25 POLE 1	99 Offic diaments and a shape of the shape	24.9 (v. ERT cate of the cate	(NGS)	MMR pro- MMR	Indianental and a second and a	Grade 3 gp and Conservation (if a molecular chair feer molecular chair feer molecular chair feer molecular chair MSS	No No Control for or only a recteristics. We will be a control for only We will be a control	International Control Inte	Low PS3 Inmo NA	No th repart deficient, no unablistochemistr

Abstract 2022-RA-376-ESGO Table 2 Clinicopathological characteristics comparison between single-and multiple-classifier

	Multiple-classifier N = 25	Single-classifier N = 253	P-valu
AGE AT DIAGNOSIS	60.9 ± 10.9	61.4 ± 12.2	0.645
Median (years) ± SD	60.9 ± 10.9	61.4 ± 12.2	0.043
BMI	25.4 ± 4.5	27.6 ± 7.3	0.271
Median (kg/m²) ± SD			
Histotype			
Endometrioid	19 (76%; 57.1-89.3%)	227 (90%; 85.5-93.0%)	0.040
Other	6 (24%; 10.7-42.9%)	26 (10%; 7.0-14.5%)	
Miometrial invasion			
<50 %	18 (72%; 52.7-86.5%)	167 (66%; 60.0-71.6%)	0.545
≥50%	7 (28%; 13.5-47.3%)	86 (34%; 28.4-40.0%)	
LVSI		Washington and American Control of the Control of t	
None or focal	22 (88%; 71.3-96.5%)	225 (89%; 84.6-92.4%)	0.888
Diffuse	3 (12%; 3.5-28.7%)	28 (11%; 7.6-15.4%)	
Grade			
Low grade (G1-2)	11 (44%; 26.1-63.2%)	183 (72%; 66.6-77.6%)	0.003
High grade	14 (56%; 36.8-73.9%)	70 (28%; 22.4-33.4%)	
Lymph nodes metastasis			
Negative	18 (72%; 52.7-86.5%)	214 (85%; 79.8%-88.6%)	0.266
ITC	2 (8%; 1.7-23.3%)	10 (4%; 2.0-6.9%)	
Micro- or macro-metastasis	5 (20%; 8.1-38.4%)	29 (12%; 8.0-15.8%)	
FIGO stage			
I	17 (68%; 48.5-83.6%)	166 (66%; 59.6-71.3%)	0.810
II - IV	8 (32%; 16.4-51.5%)	87 (34%; 28.7-40.4%)	
ESGO/ESTRO/ESP (2020) Molecular classification unknown			
Low	9 (36%; 19.5-55.5%)	115 (46%; 39.4-51.6%)	0.318
Intermediate	6 (24%; 10.7-42.9%)	30 (12%; 8.3-16.3%)	
High-Intermediate	1 (4%; 0.4-17.2%)	30 (12%; 8.3-16.3%)	
High	8 (32%; 16.4-51.5%)	65 (26%; 20.6-31.3%)	
Advanced/metastatic	1 (4%; 0.4-17.2%)	13 (5%; 2.9-8.4%)	
ESGO/ESTRO/ESP (2020) Molecular classification known			
Low	12 (48%; 29.5-66.9%)	112 (44.3%; 38.2-50.4%)	0.919
Intermediate	3 (12%; 3.5-28.7%)	29 (12%; 8.0-15.8%)	
High-Intermediate	1 (4%; 0.4-17.2%)	24 (10%; 6.3-13.6%)	
High	8 (32%; 16.4-51.5%)	75 (30%; 24.3-35.5%)	
Advanced/metastatic	1 (4%; 0.4-17.2%)	13 (5%; 2.9-8.4%)	
FOLLOW UP			
Mean (months) ± SD	6.6 ± 6.1	6.4 ± 6.3	
Number of recurrences	1 (4%; 0.4-17.2%)	15 (6%; 3.5-9.4%)	
NOTE: Data reported as Count (Column%; 959 Abbreviations: ITC, isolated tumour cells; MM			nass index;

Results A total of 278 ECs underwent molecular analysis, of which 253 (91.0%,CI 87.8–94.2) harboured a unique molecular signature, while 25 (9.0%,CI 5.8–12.2) were 'multiple-classifiers'. Among them, we identified 15 (5.4%,CI 2.9–8.3) MMRd-p53abn, 6 (2.2%,CI 0.7–4.0) POLEmut-p53abn, 2 (0.7%,CI 0.0–1.8) POLEmut-MMRd, and 2 (0.7%,CI 0.0–1.8)